Septerna, Inc. is an innovative biotechnology company focused on revolutionizing the treatment of diseases through its advanced selective protein modulation platform. Leveraging proprietary technologies and an exceptional scientific team, Septerna is committed to developing a robust pipeline of next-generation therapeutics that target critical unmet medical needs across multiple therapeutic areas. With a firm dedication to research and development, the company is well-positioned for significant growth, offering institutional investors a promising opportunity in the dynamic biopharmaceutical sector.
| Revenue (TTM) | $72.25M |
| Gross Profit (TTM) | $72.25M |
| EBITDA | $-66.56M |
| Operating Margin | -50.10% |
| Return on Equity | -9.26% |
| Return on Assets | -8.49% |
| Revenue/Share (TTM) | $1.63 |
| Book Value | $8.43 |
| Price-to-Book | 4.05 |
| Price-to-Sales (TTM) | 22.35 |
| EV/Revenue | 16.73 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12011.00% |
| Shares Outstanding | $45.08M |
| Float | $23.12M |
| % Insiders | 3.17% |
| % Institutions | 102.68% |
Volatility is currently expanding
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D.
